1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group Ltd.

1.44
EUR
+0.01
(+0.70%)
1.38BMarket Cap
Mar 24Next Earn
Consun Pharmaceutical Group Ltd.
FRA:C1P
(Frankfurt Stock Exchange)

Recent

price

1.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.46
0.75
0.73
0.85
1.28
1.93
2.16
2.04
2.15
2.55
2.96
3.28
3.61
4.03
- -
Revenue per Share
0.14
0.2
0.21
0.25
0.32
0.46
0.54
0.09
0.61
0.74
0.86
0.99
1.11
1.27
- -
Basic EPS, GAAP
0.09
0.13
0.27
0.17
0.4
0.22
0.66
0.24
1
0.78
1.13
0.97
1.19
1.35
- -
Free Cash Flow per Basic Share
- -
0.24
0.04
0.03
0.12
0.2
0.08
0.27
0.16
0.25
0.16
0.41
0.83
0.59
- -
Dividend per Share
0.36
1.26
1.43
1.64
1.81
2
2.47
2.3
2.71
3.18
3.9
4.58
4.82
5.4
5.4
Book Value per Share
0.36
1.26
1.43
1.64
0.98
1.11
1.61
1.69
2.11
2.62
3.37
4.08
4.38
4.95
4.95
Tangible Book Value per Share
1,000
759
998
981
959
861
855
849
817
801
790
791
821
848
848
Basic Weighted Avg Shares
458
572
731
831
1,223
1,660
1,844
1,728
1,753
2,045
2,340
2,590
2,967
3,417
- -
Sales/Revenue/Turnover
39.02
36
32.23
35.37
32.53
32.11
35.48
32.84
31.59
31.9
30.75
31.27
32.45
33.72
- -
Operating Margin (%)
12
13
16
19
40
67
72
73
72
73
76
78
64
67
- -
Depreciation Expense
136
153
211
250
308
396
465
80
499
590
683
785
910
1,078
- -
Net Income, GAAP
23.93
27.36
20.05
20.68
20.77
22.6
19.33
52.78
17.47
15.63
8.4
8.93
10.07
8.97
- -
Effective Tax Rate (%)
29.75
26.74
28.9
30.04
25.14
23.87
25.24
4.62
28.46
28.86
29.19
30.29
30.68
31.55
- -
Profit Margin (%)
185
1,043
1,218
731
843
1,214
1,397
1,113
1,327
1,698
2,272
2,783
3,181
3,174
3,174
Working Capital
- -
- -
- -
- -
- -
374
245
- -
- -
9
6
4
7
3
3
LT Debt
355
1,257
1,433
1,637
2,061
2,064
2,497
2,307
2,516
2,911
3,439
3,919
4,393
4,838
4,838
Total Equity
- -
18.27
15.48
16.24
16.78
17.87
18.22
2.6
16.46
17.95
18.61
19.18
20.47
22.36
- -
Return on Invested Capital (%)
- -
18.96
15.7
16.29
16.04
16.28
16.49
3.83
18
18.34
18.65
19.25
20.37
22.06
- -
Return on Capital (%)
- -
18.96
15.7
16.27
18.1
22.6
23.84
3.85
23.67
24.4
23.7
23.17
23.57
24.98
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
260
249
210
LT Borrowings
- -
- -
- -
LT Finance Leases
7
5
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
849
850
840
Market Capitalization
6,646
7,608
11,323

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
4,551
4,766
4,605
Cash, Cash Equivalents & STI
3,866
4,037
3,903
Accounts Receivable, Net
234
296
251
Inventories
290
287
271
Total Current Liabilities
1,371
1,348
1,430
Payables & Accruals
- -
- -
- -
ST Debt
260
249
210
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.85%
14%
10.13%
Free Cash Flow
56.4%
10%
16.91%
Net Income, GAAP
59.49%
16.67%
18.41%
Sales/Revenue/Turnover
16.06%
14.3%
15.17%
Total Cash Common Dividend
73.82%
50.55%
-26.77%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,590
2024
- -
- -
2,967
2025
- -
- -
3,417

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.99
2024
- -
- -
1.11
2025
- -
- -
1.27

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.41
2024
- -
- -
0.83
2025
- -
- -
0.59
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Consun Pharmaceutical Group Limited (1681.HK) is a leading pharmaceutical company engaged in the research, development, manufacture, and sale of traditional Chinese medicines and healthcare products. The company offers a comprehensive portfolio of proprietary Chinese medicine products, including renowned brands such as Mailuo Shutong Pills for cardiovascular health, Xiangsha Liujun Pills for gastrointestinal disorders, Fuke Qianjin Tablets for gynecological conditions, and Compound Danshen Dripping Pills for coronary heart disease; it also provides modern healthcare products like functional foods, nutritional supplements, and medical devices targeting consumer wellness. Headquartered in Guangzhou, China, and founded in 1997, Consun operates primarily in the domestic Chinese market with distribution networks across major provinces and select international markets in Asia. Consun's business segments encompass proprietary Chinese medicines, which form the core revenue driver through branded formulations derived from classical recipes; healthcare products including herbal extracts and wellness beverages; and research-driven innovations in biotechnology pharmaceuticals. The company serves hospitals, retail pharmacies, and direct-to-consumer channels, focusing on chronic disease management and preventive healthcare for middle-aged and elderly populations. Its manufacturing facilities adhere to GMP standards, supporting large-scale production in Guangdong province. In recent developments, Consun has expanded through strategic acquisitions, including the 2024 purchase of additional stakes in key subsidiaries to consolidate its pharmaceutical pipeline, and formed alliances with research institutions for new drug development in oncology and neurology. The company launched innovative products such as upgraded bio-fermented health supplements in late 2024, alongside a major reorganization to streamline R&D operations amid regulatory changes in China's traditional medicine sector. These initiatives, coupled with a successful funding round exceeding RMB 1 billion for digital health platforms, position Consun for sustained growth in the competitive Chinese pharma landscape.